- The European Commission (EC) has granted conditional marketing approval for Bristol Myers Squibb & Co's BMY Abecma (idecabtagene vicleucel, ide-cel) for relapsed and refractory multiple myeloma.
- Abecma is a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.
- The approval comes for patients who have received at least three prior therapies and have demonstrated disease progression on the last treatment.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: BMY shares are up 1.19% at $68.74 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
